TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02835885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digitmer High Voltage Stimulator model DS7A TENS unit

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Digitmer High Voltage Stimulator model DS7A TENS unit
Study: NCT00786877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improved biomass cookstove with exterior ventilation
Description: Improved cookstove design installed in house that is higher efficiency and is vented to the exterior.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 2 intervention arm (LPG stove)
Description: LPG two burner stove with a 12 month supply of LP gas.
Study: NCT01749384

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given PO
Study: NCT01638442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHR-2797
Description: Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.~--------------------------------------------------------------------------------
Study: NCT03830905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC221
Description: Participants will receive 200 mg XC221 once a day during 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo once a day during 3 days
Study: NCT02942953

Intervention type: DEVICE
Intervention: Diaphragmatic Pacer
Description: The surgical procedure of DP implantation consists in placing four intramuscular electrodes, using a conventional abdominal laparoscopy with four ports. It consists in locating the optimum point for electrode insertion. The process involves mapping between 30 and 50 different points in each hemidiaphragm by applying an electric stimulus of 2-24 mA at 100 µsec pulse widths11. It results in both qualitative and quantitative assessment of diaphragmatic movement. Site of main electrode is identified as the location of each hemidiaphragm's change of maximum pressure and site of secondary electrode as replica of main site. Once the sites are identified intramuscular electrode placement phase is initiated. Finally the electrodes are tunneled out to the corresponding percutaneous exit site.
Study: NCT02603224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-201
Description: Intradermal injection of single ascending doses and multiple ascending doses in healthy volunteers.
Study: NCT01337037

Intervention type: DEVICE
Intervention: VATS lobectomy using modified equipments
Description: the procedure of this group is the same with standard VATS lobectomy group.the VATS surgical equipments used in the group are designed according to the experience of chinese lobectomy surgery. All the patent applications of the surgical equipments are granted. proprietor of the patents is Jun Wang, head of Department of Thoracic surgery of people's hospital, peking university.~Details of the modified equipments: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.) consists of 8 basic surgical equipments, which are crafoord dissecting and ligature forcep, Yankauer suction tube, mixter dissecting and ligature forceps(long),mixter dissecting and ligature forceps(short), atraumatic-grip aorta-aneurysma clamp with toothing De Bakey, De Bakey atraumatic-grip vascular forcep, Bozemann tite grip needle holder, Winter placenta and ovum forcep.
Study: NCT02603224

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection of placebo at a second site in healthy volunteers. Each subject will serve as their own control.
Study: NCT02961309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: 1 High-Potency THC (Dosage = 10mg) cigarette (oral smoking) on one day and 1 Placebo on the other day.
Study: NCT01337037

Intervention type: PROCEDURE
Intervention: VATS lobectomy using less staples
Description: VATS lobectomy with at most 4 staples used, aimed at reduced hospital cost.This procedure is similar with the standard VATS lobectomy procedure without staples limits. The lobar vessels and bronchus are stapled. However, the interlobar fissures should be deal with electronic cautery, harmonic scalpel,or suturing.
Study: NCT00862979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Description: Everolimus 0.25mg, 0.75mg or 1.0mg based on blood levels (5-10 ng/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus (EVR)
Description: Everolimus 0.25mg, 0.75mg or 1.0mg based on blood levels (5-10 ng/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A (CyA)
Description: 10 mg, 25 mg, 50 mg or 100 mg capsule according to blood levels for CNI-regimen group. For CNI-free-regimen dispense on month 6 to 9 only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine A (CyA)
Description: 10 mg, 25 mg, 50 mg or 100 mg capsule according to blood levels for CNI-regimen group. For CNI-free-regimen dispense on month 6 to 9 only
Study: NCT01337037

Intervention type: PROCEDURE
Intervention: Standard VATS lobectomy
Description: VATS lobectomy without new equipments and limitation of staples, same with the current procedure of VATS lobectomy performed in thoracic departments of Peking university people's hospital and the Collaborators. All procedures were conducted under general anesthesia with double lumen intubation. The thoracoscope was introduced through 7th or 8th intercostals space on the mid-axillaries line. The 4 cm long utility incision was made on the 4th or 5th intercostals space anterior axillary's line without rib-spreading. A third retraction incision located on the 7th or 8th intercostals space sub-scapular line. The surgeon stands on the ventral side of patient using an electrocautery hook and a suction device through the utility incision. Anatomic lobectomy was performed with systemic mediastinal lymph node dissection for lung cancer patients.

Intervention type: PROCEDURE
Intervention: Open lobectomy
Description: standard lobectomy procedure by thoracotomy approach
Study: NCT00862979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus (TAC)
Description: 0.5 mg, 1 mg, or 5 mg capsule given according to blood levels for CNI-regimen. For CNI-free-regimen give on month 6 to 9 only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus (TAC)
Description: 0.5 mg, 1 mg, or 5 mg capsule given according to blood levels for CNI-regimen. For CNI-free-regimen give on month 6 to 9 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric coated mycophenolate sodium (EC-MPS)
Description: 180 mg or 360 mg tablet dosed 1440-2280 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (MMF)
Description: 250 mg or 500 mg tablets with a dose of 1500-3000 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: according to local standard: 0.05-0.3 mg/kg of prednisolone or equivalent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: according to local standard: 0.05-0.3 mg/kg of prednisolone or equivalent
Study: NCT00537030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03426241

Intervention type: OTHER
Intervention: no intervention
Description: this is cross-sectional study

Intervention type: OTHER
Intervention: no intervention
Description: this is cross-sectional study

Intervention type: OTHER
Intervention: no intervention
Description: this is cross-sectional study

Intervention type: OTHER
Intervention: no intervention
Description: this is cross-sectional study
Study: NCT01981720

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRX-102 (pegunigalsidase alfa)
Description: PRX-102 1 mg/kg every 2 weeks
Study: NCT01248104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Infusion during cardiac surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminocaproic Acid
Description: Infusion during cardiac surgery
Study: NCT04344847

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic sleeve gastrectomy
Description: Excision of Gastric GIST along fundus or body of stomach in the same specimen of LSG with safety margin 1-2cm
Study: NCT04250064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: Additional concurrent low-dose Bevacizumab with standard EBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose RT
Description: Ultra-low-dose EBRT instead of standard dose RT
Study: NCT02936102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAZ053
Description: Anti-PD-L1 Antibody
Study: NCT06461598

Intervention type: DRUG
Intervention: Chemotherapy
Description: All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle \>= 1).

Intervention type: DRUG
Intervention: Chemotherapy
Description: All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle \>= 1).
Study: NCT01964755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Study: NCT02936102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Anti-PD-1 Antibody
Study: NCT01964755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate administered starting on Day 2, per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin administered first intravenously 24 hours after start of Methotrexate infusion, then orally every 6 hours for at least 10 doses, per study protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea administered orally twice daily starting on Day 2, and continuing for a total of 10 doses, per study protocol
Study: NCT03709680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Phase 1: Administered (oral) at 55 mg/m2, 75 mg/m2, or 40 mg/m2, or 95 mg/m2 or 115 mg/m2 on days 1-14 of a 21-day cycle Phase 1 Tumor specific cohort-Neuroblastoma and Phase 2 : Administered (oral) at 75 mg/m2 on days 1-14 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Phase 1: Administered (oral) at 55 mg/m2, 75 mg/m2, or 40 mg/m2, or 95 mg/m2 or 115 mg/m2 on days 1-14 of a 21-day cycle Phase 1 Tumor specific cohort-Neuroblastoma and Phase 2 : Administered (oral) at 75 mg/m2 on days 1-14 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Phase 1: Administered (oral) at 55 mg/m2, 75 mg/m2, or 40 mg/m2, or 95 mg/m2 or 115 mg/m2 on days 1-14 of a 21-day cycle Phase 1 Tumor specific cohort-Neuroblastoma and Phase 2 : Administered (oral) at 75 mg/m2 on days 1-14 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Phase 1 and Phase 2: Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Phase 1 and Phase 2: Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Phase 1 and Phase 2: Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Phase 1 and Phase 2: Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Phase 1 and Phase 2: Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Phase 1 and Phase 2: Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Phase 1 only : Administered at 0.75 mg/m2 (intravenous), on days 1-5 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Phase 1 only : Administered at 0.75 mg/m2 (intravenous), on days 1-5 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Phase 1 only: Administered at 250 mg/m2 (intravenous), on days 1-5 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Phase 1 only: Administered at 250 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
Study: NCT02118376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 5ug bid,Subcutaneous injection
Study: NCT03805126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Legal Partnership
Description: With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care includes consultation with a social worker and a community health worker.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care includes consultation with a social worker and a community health worker.
Study: NCT01486576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voluven (Hydroxyethyl starch 130/0,4)
Description: 7,5 ml/kg in the first hour and then 5 ml/kg
Study: NCT01964755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Zidovudine administered first intravenously on Day 2, and then orally twice daily for 10 doses, per study protocol.
Study: NCT01486576

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9 mg/ml
Description: 7,5 ml/kg in the first hour and then 5 ml/kg
Study: NCT04461821

Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time SESI-MS breath analysis
Description: Participants will be asked to refrain from eating, drinking, chewing gum use or brushing their teeth at least 1 hour before the measurements will be performed. Room temperature and lighting will be set at the same level for all measurements. Participants will exhale through a disposable mouthpiece into a commercially available SESI source (FIT S.L., Spain). While performing full exhalations, the subjects will keep the pressure through the sampling line at a fixed value monitored by a digital manometer. Breath prints will be collected in real-time recording multiple replicates (typically six in positive and negative ion mode). The whole procedure is absolutely non-invasive and is usually accomplished without any effort in around 15 min per subject.

Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time SESI-MS breath analysis
Description: Participants will be asked to refrain from eating, drinking, chewing gum use or brushing their teeth at least 1 hour before the measurements will be performed. Room temperature and lighting will be set at the same level for all measurements. Participants will exhale through a disposable mouthpiece into a commercially available SESI source (FIT S.L., Spain). While performing full exhalations, the subjects will keep the pressure through the sampling line at a fixed value monitored by a digital manometer. Breath prints will be collected in real-time recording multiple replicates (typically six in positive and negative ion mode). The whole procedure is absolutely non-invasive and is usually accomplished without any effort in around 15 min per subject.
Study: NCT01964755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is optional and will be administered to study participants, per study protocol.
Study: NCT02495571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cough Assessment in ALS Patients
Description: 1. Volitional Cough assessment by spirometer:~   a) Peak Cough Espiratory Flow (PCEF)~2. Cough Reflex Test a) Peak Cough Espiratory Flow (PCEF)

Intervention type: OTHER
Group type: OTHER
Intervention: Cough Assessment in ALS Patients
Description: 1. Volitional Cough assessment by spirometer:~   a) Peak Cough Espiratory Flow (PCEF)~2. Cough Reflex Test a) Peak Cough Espiratory Flow (PCEF)
Study: NCT03511846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral capsaicin
Description: Subjects will drink a solution with capsaicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral capsaicin
Description: Subjects will drink a solution with capsaicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral capsaicin
Description: Subjects will drink a solution with capsaicin
Study: NCT04461821

Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time SESI-MS breath analysis
Description: Participants will be asked to refrain from eating, drinking, chewing gum use or brushing their teeth at least 1 hour before the measurements will be performed. Room temperature and lighting will be set at the same level for all measurements. Participants will exhale through a disposable mouthpiece into a commercially available SESI source (FIT S.L., Spain). While performing full exhalations, the subjects will keep the pressure through the sampling line at a fixed value monitored by a digital manometer. Breath prints will be collected in real-time recording multiple replicates (typically six in positive and negative ion mode). The whole procedure is absolutely non-invasive and is usually accomplished without any effort in around 15 min per subject.

Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time SESI-MS breath analysis
Description: Participants will be asked to refrain from eating, drinking, chewing gum use or brushing their teeth at least 1 hour before the measurements will be performed. Room temperature and lighting will be set at the same level for all measurements. Participants will exhale through a disposable mouthpiece into a commercially available SESI source (FIT S.L., Spain). While performing full exhalations, the subjects will keep the pressure through the sampling line at a fixed value monitored by a digital manometer. Breath prints will be collected in real-time recording multiple replicates (typically six in positive and negative ion mode). The whole procedure is absolutely non-invasive and is usually accomplished without any effort in around 15 min per subject.

Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time SESI-MS breath analysis
Description: Participants will be asked to refrain from eating, drinking, chewing gum use or brushing their teeth at least 1 hour before the measurements will be performed. Room temperature and lighting will be set at the same level for all measurements. Participants will exhale through a disposable mouthpiece into a commercially available SESI source (FIT S.L., Spain). While performing full exhalations, the subjects will keep the pressure through the sampling line at a fixed value monitored by a digital manometer. Breath prints will be collected in real-time recording multiple replicates (typically six in positive and negative ion mode). The whole procedure is absolutely non-invasive and is usually accomplished without any effort in around 15 min per subject.
Study: NCT00621062

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Ligation of the GSV
Description: Performed in local or general anesthesia in accordance to clinical praxis and the patients own preference. After high ligation the GSV is stripped from the groin to the most distant insufficient part or just under the knee joint.All proximal branches are ligated. Including the superficial epigastric vein. The stripping instrument can be inserted in either cranial or caudal direction but all veins are stripped in the cranio-caudal direction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous Laser Ablation
Description: Laser ablation is performed in tumescence anesthesia which is performed with a 150-200 ml (sometimes more is required, up to 400ml in patients with a poorly formed saphenous sheath) solution of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). Laser is performed under duplex guidance and the catheter is inserted percutaneously into the GSV at knee level and parked distant to the saphenofemoral junction (SFJ) just distal to the superficial epigastric vein. Laser ablation is performed down to the most distal insufficient part of GSV or just below the knee joint. We use an effect of 14 Watt administration of 70-80 J / cm at a continuous mode at a speed of 1cm/5sec.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: RF ablation is performed in tumescence anesthesia which is performed with a 150-200 ml solution (same as above) of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). RF is performed under duplex guidance and the Closure-FAST catheter is inserted percutaneously into the GSV at the knee level and parked distant to the SFJ just distal to the superficial epigastric vein. Probe size and length used for RF is chosen in accordance to the manufacturer's recommendation and with a probe temperature of 120 degrees C. RF closure is performed down to the most distal insufficient part of GSV or just under the knee joint.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foam Sclerotherapy
Description: Sclerosant foam consists of 2ml 3% aethoxysclerol mixed with 8ml air (Tessari method). A maximum of 10 ml is injected. Access to the vein for the sclerosant is gained by a duplex guided puncture or a mini incision mid-thigh or just above the knee and the amount of sclerosant foam used is 2,5-10 ml. Duplex is used prior to the operation in order to mark the vein and during the operation in order to control the extent of the sclerofoam. Duplex validates that foam is deposed to the whole length of the GSV. Blood from the veins is drained by means of elevation prior to the deposition of the sclerofoam. The leg is then bandaged with elastic bandage.
Study: NCT04192344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK021
Description: ABSK021 oral capsule
Study: NCT02664493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.